pentamidine has been researched along with Connective Tissue Diseases in 3 studies
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.
Connective Tissue Diseases: A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although TMP-SMX for PCP prophylaxis had to be discontinued in 43% of patients with connective tissue diseases, pentamidine and atovaquone were well tolerated." | 7.91 | Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. ( Asako, K; Kikuchi, H; Kitazawa, T; Kono, H; Ota, Y; Seo, K; Yoshino, Y, 2019) |
| "Although TMP-SMX for PCP prophylaxis had to be discontinued in 43% of patients with connective tissue diseases, pentamidine and atovaquone were well tolerated." | 3.91 | Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. ( Asako, K; Kikuchi, H; Kitazawa, T; Kono, H; Ota, Y; Seo, K; Yoshino, Y, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kitazawa, T | 1 |
| Seo, K | 1 |
| Yoshino, Y | 1 |
| Asako, K | 1 |
| Kikuchi, H | 1 |
| Kono, H | 1 |
| Ota, Y | 1 |
| Saito, K | 1 |
| Tanaka, Y | 1 |
| Kimura, M | 1 |
| Tanaka, S | 1 |
| Ishikawa, A | 1 |
| Endo, H | 1 |
| Hirohata, S | 1 |
| Kondo, H | 1 |
1 review available for pentamidine and Connective Tissue Diseases
| Article | Year |
|---|---|
[Pneumocystis carinii pneumonia in patients with connective tissue diseases].
Topics: Anti-Infective Agents; Connective Tissue Diseases; Drug Therapy, Combination; Humans; Molecular Diag | 2002 |
2 other studies available for pentamidine and Connective Tissue Diseases
| Article | Year |
|---|---|
Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antibi | 2019 |
Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease.
Topics: Adult; Aerosols; Aged; CD4 Lymphocyte Count; Connective Tissue Diseases; Female; Humans; Immunocompr | 2008 |